Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence
作者: Fabio ConfortiLaura PalaEleonora PaganGiuseppe VialeVincenzo BagnardiGiulia PeruzzottiTommaso De PasNadia BiancoRossella GraffeoElena Guerini RoccoAndrea VingianiRichard D. GelberAlan S. CoatesMarco ColleoniAron Goldhirsch
作者单位: 1Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy
2Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy
3Department of Pathology, IEO, European Institute of Oncology IRCCS & State University of Milan, Milan, Italy
4Division of Data Management, IEO, European Institute of Oncology IRCCS, Milan, Italy
5Division of Medical Senology, IEO, European Institute of Oncology IRCCS, Milan, Italy
6Institute of Oncology (IOSI) and Breast Unit (CSSI) of Southern Switzerland, Bellinzona, Switzerland
7Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology IRCCS, Milan, Italy
8Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health, and Frontier Science & Technology Research Foundation, Boston, USA
9International Breast Cancer Study Group and University of Sydney, Syd
刊名: Breast Cancer Research, 2019, Vol.21 (10), pp.1872-1881
来源数据库: Springer Nature Journal
DOI: 10.1186/s13058-019-1234-9
关键词: Lobular carcinomaLate distant recurrence riskKiCST5
英文摘要: Abstract(#br)Background(#br)Invasive lobular carcinomas (ILCs) account for 10–15% of all breast cancers. They are characterized by an elevated endocrine responsiveness and by a long lasting risk of relapse over time. Here we report for the first time an analysis of clinical and pathological features associated with the risk of late distant recurrence in ILCs. Patients and methods(#br)We retrospectively analyzed all consecutive patients with hormone receptor–positive ILC operated at the European Institute of Oncology (EIO) between June 1994 and December 2010 and scheduled to receive at least 5 years of endocrine treatment. The aim was to identify clinical and pathological variables that provide prognostic information in the period beginning 5 years after definitive surgery. The cumulative...
全文获取路径: Springer Nature  (合作)
影响因子:5.872 (2012)